{
  "docId": "019de076-9336-7344-93bc-154185328b25",
  "docSlug": "edea36d6b00ed662cafb2da1a03c41ae",
  "documentTitle": "BenevolentAI | Investor Conference Presentation Deck | 22 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 22,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "other",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Slide 6 of a presentation deck.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-9336-7344-93bc-154185328b25/6",
  "deckHref": "/decks/019de076-9336-7344-93bc-154185328b25",
  "deckJsonHref": "/decks/019de076-9336-7344-93bc-154185328b25.json",
  "deckAnchorHref": "/decks/019de076-9336-7344-93bc-154185328b25#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.21,
        "x": 0.605,
        "y": 0.105
      },
      "kind": "image",
      "text": "Merck KGaA logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3f8bdca-5ab1-4099-a546-ca8d5bc34393",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.45,
        "y": 0.35
      },
      "kind": "list",
      "text": "Oncology; Neurology; Immunology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "126dedf3-0345-4b25-9501-c3c569704c1a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "Leverages End-to-End Drug Discovery capabilities including our wet lab facility in Cambridge (UK); Identify and develop innovative small molecule compounds, through Hit Identification to preclinical stage; Initial delivery of three novel small molecule drug candidates",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a13cbf8d-5054-4303-b5a0-7421dc973a2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.5,
        "x": 0.45,
        "y": 0.58
      },
      "kind": "list",
      "text": "Up to $594 million of total value, including: Low double-digit million dollar upfront payment; Discovery, development and commercial milestones; Tiered royalties on net sales of any commercialised products",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ede7198b-0cbb-4983-bcce-095aa72df40d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.8,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "September 2023",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc4ec905-a868-4672-bda9-b8edd5dd945a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Strategic collaboration with Merck KGaA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a7f9a23-26a6-4efe-8615-1f222f2a6062",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "fc718039-c6c2-4109-9abd-2884c985bfb6",
      "evidence": "Oncology; Neurology; Immunology",
      "confidence": 0.5
    },
    {
      "name": "Capital Allocation Framework",
      "slug": "capital-allocation-framework",
      "agent": null,
      "layer": "slide",
      "matchId": "b6087e17-e06c-499c-9496-1c3f2f6cb9c9",
      "evidence": "Up to $594 million of total value, including: Low double-digit million dollar upfront payment; Discovery, development and commercial milestones; Tiered royalties on net sales of any commercialised products",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 5,
      "beatId": "5e794bc6-a251-4149-a985-6241ead7f855",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides on strategic collaborations and pipeline products showcase the solution.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "0a7dc950-f012-4806-a974-ccc12cfbaec1",
      "evidence": "The presentation emphasizes the potential of the Benevolent Platform™.",
      "position": 0,
      "objective": "Highlighting the importance of AI-driven drug discovery",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}